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Catching the low-hanging fruit in medicines optimisation 
 
 
Rita Faria, Mark Sculpher, Centre for Health Economics, University of York, UK 
Evidence on effectiveness and cost-effectiveness of interventions 
This work was funded under the Economic Evaluation Policy Research Unit (EEPRU) which receives funding from the Department of Health Policy Research Programme. EEPRU is a collaboration between researchers from two institutions (Centre for Health Economics, University of York and School of Health and 
Related Studies, University of Sheffield). The views expressed in this article are those of the authors and not necessarily those of the Department of Health. 
More details and a full report will be available at http://www.eepru.org.uk/ 
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How to best to achieve medicines optimisation? 
Better health outcomes 
Medicines optimisation 
1. Patient experience 
Shared decision-making 
Supporting patients 
Adherence to medicines 
2. Safety 
Safe and secure use of medicines 
Avoid adverse drug events 
Avoid adverse drug reactions 
3. Effectiveness and cost-effectiveness 
Evidence based-practice 
Decisions transparent and robust 
Decisions in accordance with the NHS 
Constitution 
Discontinuation of medicines no longer required 
or deemed not cost-effective 
4. Integrate medicines optimisation in routine practice 
Savings ~ $500 million/year 
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Conclusions Directions for future research 
 Research has evaluated interventions on one particular stage of the medicines pathway 
 Process outcomes are often used rather than end outcomes (health outcomes, costs) 
 Remains unclear: 
 Which aspect of suboptimal use of medicines is a key driver of costs and health loss 
 Which stage of the medicines pathway is more likely to benefit from intervention 
 Decision analytic modelling of the full medicines pathway 
 To evaluate which  aspects of suboptimal medicines use have the most impact 
 To indicate where an intervention could provide the greatest benefits 
 To estimate the how much to invest in improving the pathway 
